The validation of these results by IHC and IF in a substantial independent cohort of 128 DLBCL and 38 non-tumor control samples on TMAs allowed confirming the significantly higher proportion of pro-inflammatory (CD86+) cells than suppressive (CSF1-R+) cells in DLBCL compared with controls, and also the overexpression of beclin-1 and Bcl-2 in DLBCL. The gene discussed is CD86; the disease is neoplasm.